Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls
Larger BMD gains in osteoporosis patients transitioning to denosumab versus other active controls
Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and metaanalysis
Expert Opin Drug Saf. 2018 Apr;17(4):413-428Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
6 randomized controlled trials were included in this meta-analysis which aimed to compare increase in bone mineral density measurements between denosumab and other active anti-osteoporosis medications among postmenopausal women with osteoporosis and who had previously been administered anti-osteoporosis therapy. In pooled analyses, percent increase in bone mineral density measured at the total hip...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.